All That Glitters: Bristol/Merck's Muraglitazar Will Be Pargluva

The companies release Phase II and III data for the dual PPAR agonist at the American Diabetes Association annual meeting. Pargluva showed a statistically significant difference in reduction of A1C levels versus Lilly/Takeda's Actos in type 2 diabetes patients in the 24-week Phase III trial.